Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP Bolus vs Infusion in Type 2 Diabetes
NCT02673554Phase 1Completed
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
- Start
- May 2004
- Primary completion
- Dec 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of glucose-dependent insulinotropic polypeptide[1-42] in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Diabeteszentrum Bad Lauterberg im Harz. Primary endpoint: Insulin secretory response after GIP bolus or infusion at 210 minutes. Started May 2004; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02673554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673554.